12,372 trials
Ovarian Cancer
Primary: Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011) — 92.3; 78.8 percentage of participants
Venous Thromboembolism · Deep Vein Thrombosis (DVT) · Pulmonary Embolism (PE)
Primary: Symptomatic Recurrent VTE, i.e., the Composite of DVT, Non-fatal PE, and Fatal PE — 130; 146 number or participants with an event — p=<0.0001
Non-Small Cell Lung Cancer
Primary: Investigator-assessed Duration of Progression-free Survival — 11.0; 5.5 Months
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 6.86; 7.00 weeks — p=0.671
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Who Died (All Participants; Data Cutoff: 07 September 2010) — 81.0; 77.8 percentage of participants
HIV/AIDS
Primary: Change on Malondialdehyde After Treatment With Omega 3 Acids for 6 Months Compared With Placebo in HIV Seropositive Patients — -1.18; -0.9 nM/mg protein
Diastolic Heart Failure · Heart Failure, Congestive
Primary: Exercise Intolerance — 13.5; 13.3; 13.6; 13.5 ml/kg/min
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 14 Weeks Between Treatment Groups — -0.83; 0.14 percentage of glycosylated haemoglobin
Epilepsy
Primary: Evaluate the Safety of USL255 Through the Collection of Adverse Events and Clinical Laboratory Evaluations — 210; 146; 102; 15 participants
Dupuytren's Contracture
Primary: Percent Change From Baseline in Total Fixed Flexion — 75.5 percentage of contracture change
Seasonal Allergic Rhinitis · SAR
Primary: Change From Baseline in the Average Morning (AM) and Evening (PM) Subject-Reported Reflective Total Nasal Symptom Score (rTNSS) During the Two Weeks of Treatment — -1.9…
Meningococcal Disease · Meningococcal Meningitis
Primary: Human Serum Bactericidal Activity (hSBA) Geometric Mean Titers (GMTs) Against 3 Neisseria.Meningitidis (N. Meningitidis) Serogroup B Reference Strains. — 111; 111; 9.27…
Dupuytren's Contracture
Primary: Percent Change From Baseline in Total Fixed Flexion — 74.41 percentage of contracture change
Venous Thromboembolism
Primary: Incidence of Subjects With Venous Thromboembolism Events. — 7.4; 13.9 percent of participants with VTE events — p=<0.001
High Risk Neuroblastoma
Primary: Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome…